Company: MIRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024077
Chunk: 33

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 33
---
. In addition, we currently have access to approximately $6.6 million in available capital through our at-the-market (ATM) offering
facility (Note 5 of accompanying financial statements), which we may utilize to further strengthen our stockholders’ equity position.
On May 7, 2025, Nasdaq accepted our plan and granted an extension to regain compliance with the Rule. The terms of the extension are
as follows: on or before October 6, 2025 the company must complete the financing transactions and evidence compliance with the Rule.

On
July 1, 2025, under the ATM Agreement, the Company sold and issued 17,373
shares of common stock at an average price per share of $1.3121 and received net proceeds of approximately $0.2 million after deducting
commissions and other fees of $570.

On July 3, 2025, the Company, sold a total of 1,540,741 shares of its common stock, par value $0.001, in block sales
to an institutional investor, at an average price of $1.2981 share (a premium to the prior days close), through its at-the-market equity
offering facility (the “Offering”). Gross proceeds from the Offering totaled approximately $2.0 million, prior to deducting
fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the StockBlock platform. The Offering
did not include any warrants.

There can be no assurance
that we will be able to maintain compliance with Nasdaq’s listing requirements. If we fail to regain compliance with the Rule,
our common stock may be subject to delisting from the Nasdaq Capital Market, which could materially and adversely affect the liquidity
and market price of our common stock and limit our access to capital.

Item
3. Quantitative and Qualitative Disclosures About Market Risk

We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and therefore are not required to provide the information
under this item per Item 305(e) of Regulation S-K.

Item
4. Controls and Procedures

Evaluation
of Disclosure Controls and Procedures

As
of the end of the period covered by this Report, our management, with the participation of our Chief Executive Officer (our principal
executive officer) and our Chief Financial Officer (our principal financial officer) (the “Certifying Officers”), conducted
evaluations of